JP2025539145A5 - - Google Patents

Info

Publication number
JP2025539145A5
JP2025539145A5 JP2025529229A JP2025529229A JP2025539145A5 JP 2025539145 A5 JP2025539145 A5 JP 2025539145A5 JP 2025529229 A JP2025529229 A JP 2025529229A JP 2025529229 A JP2025529229 A JP 2025529229A JP 2025539145 A5 JP2025539145 A5 JP 2025539145A5
Authority
JP
Japan
Prior art keywords
antibody
multispecific
bispecific antibody
bispecific
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025529229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025539145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/132564 external-priority patent/WO2024109678A1/en
Publication of JP2025539145A publication Critical patent/JP2025539145A/ja
Publication of JP2025539145A5 publication Critical patent/JP2025539145A5/ja
Pending legal-status Critical Current

Links

JP2025529229A 2022-11-21 2023-11-20 抗ｃｄ１３７抗体及びその使用方法 Pending JP2025539145A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2022133148 2022-11-21
CNPCT/CN2022/133148 2022-11-21
CNPCT/CN2022/133147 2022-11-21
CN2022133147 2022-11-21
CN2023126252 2023-10-24
CNPCT/CN2023/126252 2023-10-24
PCT/CN2023/132564 WO2024109678A1 (en) 2022-11-21 2023-11-20 Anti-cd137 antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2025539145A JP2025539145A (ja) 2025-12-03
JP2025539145A5 true JP2025539145A5 (https=) 2026-04-14

Family

ID=91195249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025529229A Pending JP2025539145A (ja) 2022-11-21 2023-11-20 抗ｃｄ１３７抗体及びその使用方法

Country Status (13)

Country Link
US (1) US20250154279A1 (https=)
EP (1) EP4623005A1 (https=)
JP (1) JP2025539145A (https=)
KR (1) KR20250110345A (https=)
CN (2) CN121378482A (https=)
AR (1) AR131126A1 (https=)
AU (1) AU2023384497A1 (https=)
CL (1) CL2025001474A1 (https=)
CO (1) CO2025006994A2 (https=)
IL (1) IL320949A (https=)
MX (1) MX2025005847A (https=)
TW (1) TW202421665A (https=)
WO (1) WO2024109678A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6845846B6 (ja) * 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
AU2018224094B2 (en) * 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
AU2018301393B2 (en) * 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
EP3710478A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Molecules that bind to cd137 and psma
CN110003332B (zh) * 2018-01-05 2021-05-11 上海原能细胞医学技术有限公司 Cd137抗体及其应用
CN120098128A (zh) * 2019-01-02 2025-06-06 Qlsf生物治疗药物公司 Cd137激动剂抗体及其用途

Similar Documents

Publication Publication Date Title
JP2026048925A5 (https=)
JP2024012451A5 (https=)
JP2026012786A5 (https=)
JP2010509937A5 (https=)
JP2024037765A5 (https=)
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
Felice Size and composition of public investment, sectoral composition and growth
JP2025023938A5 (https=)
JPWO2020075746A5 (https=)
JP2021504412A5 (https=)
JP2013198490A5 (https=)
JP2025512391A5 (https=)
JP2009260173A5 (https=)
JP2022538215A5 (https=)
JP2025118771A5 (https=)
JP2023525815A5 (https=)
JP2023103231A5 (https=)
JP2025038009A5 (https=)
JP2023139025A5 (https=)
JP2011509650A5 (https=)
JP2024160274A5 (https=)
JP2025163046A5 (https=)
JP2024038101A5 (https=)
JP2024156672A5 (https=)
JP2025539145A5 (https=)